scholarly journals Alloreactive cytotoxic T lymphocyte immunotherapy treatment of a patient with metastatic prostate cancer

Medicine ◽  
2018 ◽  
Vol 97 (24) ◽  
pp. e11111
Author(s):  
Junfeng Shi ◽  
Yi Chen ◽  
Yuetong Chen ◽  
Yunzhu Shen ◽  
Huanyu Zhao ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
T Lymphocyte ◽  
Metastatic Prostate Cancer ◽  
Cytotoxic T Lymphocyte ◽  
Lymphocyte Immunotherapy

scholarly journals HLA-A2-restricted Cytotoxic T Lymphocyte Epitopes from Human Hepsin as Novel Targets for Prostate Cancer Immunotherapy

2013 ◽  
Vol 78 (3) ◽  
pp. 248-257 ◽  
Author(s):  
J. Guo ◽  
G. Li ◽  
J. Tang ◽  
X.-B. Cao ◽  
Q.-Y. Zhou ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Immunotherapy ◽  
T Lymphocyte ◽  
Cytotoxic T Lymphocyte ◽  
Novel Targets

scholarly journals Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy

2014 ◽  
Vol 211 (4) ◽  
pp. 715-725 ◽  
Author(s):  
Xiaozhou Fan ◽  
Sergio A. Quezada ◽  
Manuel A. Sepulveda ◽  
Padmanee Sharma ◽  
James P. Allison
Keyword(s):  
Prostate Cancer ◽  
Monoclonal Antibody ◽  
Immune Responses ◽  
Tumor Cell ◽  
Cancer Patients ◽  
T Lymphocyte ◽  
Cytotoxic T Lymphocyte ◽  
Strong Support ◽  
Antitumor Effects ◽  
Tumor Cell Vaccines

Cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade with a monoclonal antibody yields durable responses in a subset of cancer patients and has been approved by the FDA as a standard therapy for late-stage melanoma. We recently identified inducible co-stimulator (ICOS) as a crucial player in the antitumor effects of CTLA-4 blockade. We now show that concomitant CTLA-4 blockade and ICOS engagement by tumor cell vaccines engineered to express ICOS ligand enhanced antitumor immune responses in both quantity and quality and significantly improved rejection of established melanoma and prostate cancer in mice. This study provides strong support for the development of combinatorial therapies incorporating anti–CTLA-4 and ICOS engagement.

scholarly journals Cytotoxic T-lymphocyte Immunotherapy for Ovarian Cancer

2012 ◽  
Vol 35 (2) ◽  
pp. 196-204 ◽  
Author(s):  
Stephen E. Wright ◽  
Kathleen A. Rewers-Felkins ◽  
Imelda S. Quinlin ◽  
Catherine A. Phillips ◽  
Mary Townsend ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
T Lymphocyte ◽  
Cytotoxic T Lymphocyte ◽  
Lymphocyte Immunotherapy
Sign in / Sign up

Export Citation Format

Share Document